No Data
No Data
Wan Nianqing: 2024 Semi-Annual Report Summary
Wan Nianqing: 2024 Semi-Annual Report
Guangdong Wannianqing (301111.SZ): The net income in the first half of the year was 15.1038 million yuan, a year-on-year decrease of 39.11%.
Jiangxi Wannianqing Cement (301111.SZ) announced its semi-annual report for 2024, with a total operating income of 0.152 billion yuan, a year-on-year increase of 3.77%; net profit attributable to shareholders of the listed company was 15.1038 million yuan, a year-on-year decrease of 39.11%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 8.5578 million yuan, a year-on-year decrease of 49.52%; basic earnings per share was 0.0944 yuan.
Jiangxi Wannianqing Cement (000789.SZ): The company's current aggregate production capacity is 15 million tons per year.
Jiangxi Wannianqing Cement (000789.SZ) stated on the investor interactive platform that the company's current aggregate production capacity is 15 million tons per year, with its main raw material being the tailings from its own cement mines. In the future, the company will increase its acquisition and storage of mining resources such as cement and aggregates, further enhancing its development potential.
Jiangxi Wannianqing Cement (000789.SZ) has paid out a total dividend of 3.4 billion yuan since its listing, which is 3.9 times the total raised funds.
Jiangxi Wannianqing Cement (000789.SZ) stated on its investor interaction platform that the company's operational development has been steadily strong in recent years. Since listing, the company has accumulated dividends of 3.4 billion yuan, which is 3.9 times the accumulated funds raised, providing good returns to investors. In the future, all employees of the company will continue to work hard and strive to create greater value for the company and shareholders.
Jiangxi Wannianqing Cement (301111.SZ): Currently no involvement in traditional Chinese medicine planting business.
Jiangxi Wannianqing Cement (301111.SZ) stated on the investor interaction platform on July 11 that the company has no current involvement in the planting industry of traditional Chinese medicine. The company focuses on the research and development, production and sales of Chinese patent medicine, and has a close relationship with upstream traditional Chinese medicine materials. The fluctuation of traditional Chinese medicine material prices has a certain degree of impact on the company's production costs, while the company's product prices are considered comprehensively based on objective environment, market demand, and product costs, so the impact of traditional Chinese medicine material price increases on the company's performance cannot be generalized.
No Data
No Data